Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nuvisertib in advanced solid tumors
NCT03715504Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nuvisertib in solid tumor (advanced stage), sponsored by Sumitomo Pharma America. Primary endpoints: Incidence of dose-limiting toxicities at 28 days and Maximum Tolerated Dose at 20 months. Started Apr 2019; status: completed.
02
Drugs
nuvisertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03715504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03715504.